Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 628-635

  Bregni, M ^a   Siena, S ^a   Di Nicola, M ^a   Dodero, A ^a   Peccatori, F ^a   Ravagnani, F ^a   Danesini, G ^a   Laffranchi, A ^a   Bonadonna, G ^a   Gianni, A M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; MESNA; METHOTREXATE; VINCRISTINE;

ADULT; ARTICLE; BONE MARROW TOXICITY; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DYSPNEA; FEMALE; FEVER; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTOSIS; MALE; MYALGIA; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RASH; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION;

EID: 9044236165     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.628     Document Type: Article

References (20)

1. Lieschke GJ, Burgess AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (second of two parts). N Engl J Med 327:99-106, 1992
2. Gianni AM, Bregni M, Siena S, et al: Recombinant human granulocyte-macrophage colony stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 8:768-778, 1990
3. Gianni AM, Siena S, Bregni M, et al: Granulocyte-macrophage colony stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 2:580-585, 1989
4. Peters WP, Rosner G, Ross M, et al: Comparative effects of granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 81:1709-1719, 1993
5. Sheridan WP, Begley CG, Juttner CA, et al: Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640-644, 1992
6. Gianni AM, Siena S, Bregni M, et al: Prolonged disease-free survival after high-dose sequential chemoradiotherapy and hemopoietic autologous transplantation in poor prognosis Hodgkin's disease. Ann Oncol 2:645-653, 1991
7. Gianni AM, Bregni M, Siena S, et al: Prospective randomized comparison of MACOP-B vs GM-CSF-supported high-dose sequential chemoradiotherapy in diffuse large cell lymphoma. Proc Am Soc Clin Oncol 10:274, 1991 (abstr)
8. Gianni AM, Siena S, Bregni M, et al: Growth factor-supported high-dose sequential (HDS) adjuvant chemotherapy in breast cancer with ≥ 10 positive nodes. Proc Am Soc Clin Oncol 11:60, 1992 (abstr)
9. + hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony stimulating factor. Blood 74:1905-1914, 1989
10. Siena S, Bregni M, Brando B, et al: Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 77:400-409, 1991
11. Tarella C, Ferrero D, Bregni M, et al: Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and GM-CSF. Eur J Cancer 27:22-27, 1991
12. Ravagnani F, Siena S, Bregni M, et al: Large-scale collection of circulating hematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. Eur J Cancer 26:562-568, 1991
13. Lieschke GJ, Cebon J, Morstyn G, et al: Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor. Blood 74:2634-2643, 1989
14. Gianni AM, Bregni M, Siena S, et al: Granulocyte-macrophage colony stimulating factor or granulocyte-colony stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. J Clin Oncol 10:1955-1962, 1992
15. Bronchud MH, Scarffe JH, Tatcher N, et al: Phase I/II study of granulocyte-colony stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56:809-813, 1987
16. Brandt SJ, Peters WP, Atwater SK, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318:869-876, 1988
17. Kessinger A, Bishop M, Armitage JO, et al: Subcutaneous (sc) and intravenous (iv) administration of rhGM-CSF for peripheral blood stem cell mobilization. Exp Hematol 22:774, 1994 (abstr)
18. Aglietta M, Monzeglio C, Piacibello W, et al: GM-CSF: Intravenous versus subcutaneous treatment. Leukemia 4:523, 1990 (abstr)
19. Zauli G, Vitale L, Brunelli MA, Bagnara GP: Prevalence of the primitive megakaryocyte progenitors (BFU-Meg) in adult human peripheral blood. Exp Hematol 20:850-854, 1992
20. Siena S, Bregni M, Di Nicola M, et al: Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. Ann Oncol 5:935-941, 1994